The type 2 diabetes (T2D) therapy market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging therapies will be predominantly later-to-market entrants of existing drug classes or combination treatments. Notable market growth is expected from the sodium glucose cotransporter-2 (SGLT-2) inhibitors and the glucagon-like peptide-1 (GLP-1) receptor agonists due to their efficacy in glycemic control and weight loss and demonstration of cardiovascular (CV) benefits, although they will face reimbursement hurdles and an increasingly stringent regulatory environment. Consequently, a high unmet need exists for affordable drugs that can safely and effectively control T2D in the long term.

QUESTIONS ANSWERED

  • How do endocrinologists rate current T2D drug classes such as the DPP-IV inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists as well as long-acting, short-acting, and rapid-acting insulins?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • What trade-offs across different clinical attributes and prices are needed from new antidiabetic drugs in order to be preferred by endocrinologists?
  • Is an injectable drug with CV benefits preferable to an oral drug offering stronger glycemic control? Discover the answer with DRG’s fully customizable Target Product Profile (TPP) simulator.

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 61 U.S. and 30 European endocrinologists fielded in August 2019.

Key companies: Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Johnson & Johnson, Merck, Mitsubishi Tanabe Pharma, Boehringer Ingelheim.

Key drug classes: DPP-IV inhibitors, SGLT-2 inhibitors, GLP-1 receptor agonists (once daily), GLP-1 receptor agonists (once weekly), long-acting insulins, short-acting insulins, rapid-acting insulins.

Table of contents

  • Detailed, Expanded Analysis: Injectables (US/EU)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
        • Nonclinical Factors
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Type 2 Diabetes
      • Key Findings: Unmet Need in Type 2 Diabetes and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Type 2 Diabetes Market and Emerging Therapy Insights
        • Opportunity: An Agent with Benefits in a Wider Range of Cardiovascular Diseases
        • Opportunity: An Agent with Improved Renal Benefits
        • Opportunity: An Agent with Weight-Loss Efficacy
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Type 2 Diabetes Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
        • Scenario 3
    • Appendix
      • Bibliography

Author(s): Rameshwar Prajapati, Ph.D., M.S. (Pharm.)

Rameshwar Prajapati, (Pharm.), is a business insights analyst in Decision Resources Group’s cardiovascular, metabolic, renal, and hematologic disorders team, focusing primarily on obesity. In this role, his main function is to perform primary and secondary research related to obesity and its treatment, as well as providing insights and assessments for the major pharmaceutical markets regarding weight loss medications. Rameshwar holds a bachelor’s degree in pharmacy from Dr. Gour University, Sagar, India. He obtained his master’s and doctorate degree in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, Nagar, India. Rameshwar also received a German Academic Exchange Service (DAAD) fellowship to conduct his research on P-glycoprotein at the University of Bonn, Germany.


Related Reports

Type 2 Diabetes | Geographic Focus: China | Type 2 Diabetes | China In-Depth | China

Type 2 diabetes (T2D) is one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Traditional therapies such as...

View Details

Type 2 Diabetes | Landscape & Forecast | Disease Landscape & Forecast

The type 2 diabetes therapy market will steadily expand over the 2017-2027 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the diseas...

View Details

Type 2 Diabetes | Access & Reimbursement | Detailed, Expanded Analysis (EU) Top 5 European Markets

MARKET OUTLOOK Type 2 diabetes (T2D) has an extremely high prevalence in the top five European markets (France, Germany, Italy, Spain, UK). Low-cost metformin (Merck Kg...

View Details

Type 2 Diabetes | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Metformin and the sulfonylureas are the most heavily prescribed drugs in T2D and dominate the early lines of therapy prior to disease progression, which requi...

View Details